| scholarly article | Q13442814 |
| P2093 | author name string | A Y Truong | |
| T P Nicolaides | |||
| P2860 | cites work | Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. | Q55481914 |
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| The 2007 WHO classification of tumours of the central nervous system | Q24685772 | ||
| ToBRAFor Not toBRAF: Is That Even a Question Anymore? | Q26829788 | ||
| Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. | Q27851711 | ||
| Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study | Q27851971 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas | Q28299301 | ||
| CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. | Q30427255 | ||
| Diffuse brainstem glioma in children: critical review of clinical trials | Q31033307 | ||
| B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression | Q33934897 | ||
| Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. | Q34193749 | ||
| Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner. | Q34206051 | ||
| Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma | Q34354839 | ||
| Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. | Q34415484 | ||
| Childhood brain tumor epidemiology: a brain tumor epidemiology consortium review | Q34642123 | ||
| Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group | Q34722440 | ||
| The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? | Q34781888 | ||
| Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience | Q34810764 | ||
| Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. | Q35146078 | ||
| Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. | Q36297064 | ||
| Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner. | Q36464991 | ||
| Targeted therapy for BRAFV600E malignant astrocytoma. | Q36800148 | ||
| Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. | Q36836677 | ||
| Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas | Q37055286 | ||
| The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. | Q39904260 | ||
| AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 | ||
| MAPping the genomic landscape of low-grade pediatric gliomas | Q42574727 | ||
| BRAF-V600E mutation in pediatric and adult glioblastoma. | Q42739240 | ||
| Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series | Q44888492 | ||
| Pilocytic astrocytoma in a child with Noonan syndrome. | Q45924221 | ||
| Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells | Q46486969 | ||
| Mutational and expression analysis of the NF1 gene argues against a role as tumor suppressor in sporadic pilocytic astrocytomas | Q48465073 | ||
| BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. | Q54587637 | ||
| P577 | publication date | 2015-07-18 | |
| P1433 | published in | Brain disorders & therapy | Q27724346 |
| P1476 | title | Targeted Therapy for MAPK Alterations in Pediatric Gliomas | |
| P478 | volume | Suppl 2 |
Search more.